Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS)
Status:
Not yet recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine efficacy of guanfacine immediate release (GIR) for
the treatment of hyperactivity/impulsivity and inattention in children 6-12 years of age with
Down syndrome (DS) after 8 weeks of treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Rachel G. Greenberg, MD, MB, MHS
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) The Emmes Company, LLC